FDA
-
-
-
-
-
-
-
Regenxbio Inc. (RGNX) PT Raised to $18 at Leerink
-
-
-
-
-
-
-
REGENXBIO Announces Positive Topline Results from Pivotal Phase III AFFINITY DUCHENNE® Study of RGX-202
-
-
-
-
-
-
-
Truist on Head of CBER at FDA Exit: 'we anticipate a positive stock reaction for IRON CAPT RGNX QURE'
-
-
-
-
-
-
-
Class Action Filed Against REGENXBIO Inc. (RGNX) - April 14, 2026 Deadline to Join – Contact The Gross Law Firm
-
-
-
-
-
-
-
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against REGENXBIO Inc. (RGNX)
-
-
-
-
-
-
-
Stifel on Regenxbio Inc. (RGNX): PT $45, 'should NOT impact RGX-202 and RGX-314'
-
-
-
-
-
-
-
REGENXBIO Reports Third Quarter 2025 Financial Results and Operational Highlights
-
325,591 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

